CDR2 and breast carcinoma: Peters et al. studied anti-Yo PCD associated with breast cancer and found antigen amplification in twelve of the seventeen tumours, with CDR2L amplification in nine of the fourteen samples (64.3%) and CDR2 amplification in two of the fourteen samples (14.3%) [12].